Download PDF

1. Company Snapshot

1.a. Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.


Esperion Therapeutics, Inc.was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Show Full description

1.b. Last Insights on ESPR

The recent 3-month performance of Esperion Therapeutics, Inc. was negatively impacted by a Q4 loss, which lagged revenue estimates. The company's FY24 total revenue grew 186% year-over-year to $332.3 million, but the U.S. net product revenue grew only 48% year-over-year to $115.7 million. Additionally, Esperion's partnership with CSL Seqirus to commercialize NEXLETOL and NEXLIZET in Australia may not have generated significant revenue yet. The company's plans to study bempedoic acid in pediatric familial hypercholesterolemia may also be a long-term strategy.

1.c. Company Highlights

2. Esperion's 2025: Record Revenue, Strong Cash, and a Clear Path Forward

In 2025, Esperion reported a staggering $168.4 million in Q4 revenue, up 144% YoY, with US net product revenue rising 38% and collaboration revenue soaring 232%. The company posted an operating margin of 20% and a diluted EPS of $0.22, just shy of analyst estimates of $0.23. Cash balances topped $167.9 million, giving the firm a solid runway for the Corstasis acquisition and Enbumyst launch. Valuation metrics reflect a company trading at a modest 12.85× EV/EBITDA and 1.06× P/S, while a negative P/E of –21.39 underscores the market’s expectation of significant growth. The robust ROIC of 23.66% signals efficient capital deployment amid expanding revenue streams.

Publication Date: Apr -17

📋 Highlights
  • Corstasis Acquisition Expansion:: Esperion acquires Corstasis for $4B+ US heart failure market access, combining bempedoic acid with Enbumyst, a first-in-class intranasal diuretic.
  • 2025 Financial Growth:: Q4 revenue surged 144% to $168.4M, with US net product revenue up 38% YoY and collaboration revenue rising 232%.
  • US Commercial Momentum:: 38% Q4 sales growth, 34% retail prescription increase, and 25% rise in prescribing HCPs for NEXLETOL/NEXLIZET, driven by statin-intolerant patient focus.
  • Triple Combination Development:: Programs aim for 70% LDL-C reduction, with NDA filings expected by 2027, leveraging bempedoic acid’s 46% hsCRP reduction advantage over non-statins.
  • Global Franchise Growth:: Otsuka’s Japan launch exceeded expectations, Daiichi Sankyo’s Europe royalty revenue up 51% YoY, and ACC guidelines reinforcing bempedoic acid’s market position.

Revenue Surge

Esperion’s Q4 sales growth was driven by a 38% increase in US net product revenue, propelled by expanding payer coverage for statin‑intolerant patients and a 25% rise in prescribers of NEXLETOL and NEXLIZET. International partners also contributed, with Daiichi Sankyo Europe reporting a 51% rise in royalty revenue and Otsuka’s Japanese launch surpassing expectations.

Profitability & Margin

Operating expenses for 2026 are projected between $225 million and $255 million, reflecting a 26% rise in R&D and a 12% increase in SG&A. Despite higher spend, the company’s operating margin remains healthy at 20%, supported by strong product mix and favorable reimbursement landscapes.

Cash Position & Debt

With $167.9 million in cash and a net debt/EBITDA ratio of 6.06, Esperion maintains a comfortable balance sheet. The firm’s free cash flow yield of –3.03% indicates early-stage investment in growth initiatives, particularly the pending Corstasis acquisition expected to close in Q2 2026.

Guidelines & Market Dynamics

Recent ACC and European dyslipidemia guideline updates have positioned bempedoic acid as a first‑line non‑statin therapy, driving a 38% uptick in US prescriptions. The company anticipates further momentum as the 2026 guidelines roll out, leveraging its cardiovascular sales force to broaden prescriber awareness.

Triple Combination Strategy

Esperion is advancing a triple‑combination therapy (bempedoic acid, ezetimibe, statin) with regulatory filings slated for 2027. Early market research indicates strong physician interest, especially in Europe, where the product could rival injectable and emerging oral options by reducing LDL‑cholesterol up to 70%.

Corstasis Acquisition Impact

The acquisition will grant global rights to Enbumyst, an intranasal diuretic for heart failure, edema, and renal disease. This move expands Esperion beyond lipid management into a $4 billion US outpatient heart‑failure market, complementing its existing cardiology portfolio and offering a differentiated treatment pathway.

Future Outlook

3. NewsRoom

Card image cap

Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference

Apr -15

Source: defenseworld.net

Card image cap

Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co.

Apr -06

Source: defenseworld.net

Card image cap

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Apr -02

Source: globenewswire.com

Card image cap

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Apr -02

Source: globenewswire.com

Card image cap

Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference

Mar -17

Source: defenseworld.net

Card image cap

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

Mar -16

Source: globenewswire.com

Card image cap

Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $8.25

Mar -16

Source: defenseworld.net

Card image cap

ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down

Mar -11

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.08%)

6. Segments

Therapies

Expected Growth: 9.08%

Esperion Therapeutics' 9.08% growth is driven by increasing adoption of its oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies, particularly Nexletol and Nexlizet. Strong sales momentum, expanded payer coverage, and growing awareness among healthcare professionals contribute to the growth. Additionally, the company's strategic partnerships and ongoing clinical trials for new indications further support its upward trajectory.

7. Detailed Products

Nexletol

Nexletol (bempedoic acid) is an oral, once-daily, non-statin LDL-C lowering therapy that inhibits the ATP citrate lyase (ACL) enzyme, a key regulator of cholesterol synthesis in the liver.

Nexlizet

Nexlizet (bempedoic acid and ezetimibe) is a once-daily, oral tablet that combines the LDL-C lowering effects of Nexletol (bempedoic acid) with the cholesterol absorption inhibitor ezetimibe.

8. Esperion Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Esperion Therapeutics, Inc. operates in a highly competitive industry with many established players, which increases the threat of substitutes. However, the company's focus on developing innovative treatments for cardiovascular diseases helps to differentiate its products and reduce the threat of substitutes.

Bargaining Power Of Customers

Esperion Therapeutics, Inc. sells its products primarily to wholesalers, distributors, and pharmacies, which have limited bargaining power. The company's strong relationships with its customers and its ability to provide high-quality products reduce the bargaining power of customers.

Bargaining Power Of Suppliers

Esperion Therapeutics, Inc. relies on a limited number of suppliers for the raw materials and services necessary to manufacture its products. While the company has some bargaining power due to its size and reputation, the concentration of suppliers in the industry increases their bargaining power.

Threat Of New Entrants

The pharmaceutical industry is highly regulated, and the barriers to entry are high. However, the potential for high profits and the growing demand for cardiovascular treatments attract new entrants. Esperion Therapeutics, Inc. must continue to innovate and differentiate its products to maintain its competitive advantage.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players and new entrants vying for market share. Esperion Therapeutics, Inc. operates in a crowded market, and the intensity of rivalry is high due to the high stakes and the need to constantly innovate and improve products.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 648.63%
Debt Cost 8.39%
Equity Weight -548.63%
Equity Cost 8.39%
WACC 8.39%
Leverage -118.23%

11. Quality Control: Esperion Therapeutics, Inc. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Phibro Animal Health

A-Score: 5.3/10

Value: 4.0

Growth: 5.2

Quality: 4.7

Yield: 4.0

Momentum: 10.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
ANI Pharmaceuticals

A-Score: 5.1/10

Value: 4.6

Growth: 6.0

Quality: 4.5

Yield: 0.0

Momentum: 9.5

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Aquestive Therapeutics

A-Score: 4.5/10

Value: 8.0

Growth: 3.7

Quality: 5.8

Yield: 0.0

Momentum: 8.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Evolus

A-Score: 4.3/10

Value: 9.2

Growth: 6.9

Quality: 6.2

Yield: 0.0

Momentum: 1.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Esperion Therapeutics

A-Score: 4.2/10

Value: 8.8

Growth: 5.9

Quality: 5.2

Yield: 0.0

Momentum: 4.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
OptiNose

A-Score: 4.0/10

Value: 7.4

Growth: 4.4

Quality: 5.1

Yield: 0.0

Momentum: 5.5

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.02$

Current Price

2.02$

Potential

-0.00%

Expected Cash-Flows